A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

CEO Joaquin Duato said the company is positioned for sustained growth in coming years even as competition batters Stelara, ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

On the company’s Q4 earnings call where an eyepopping $88.8 billion in full-year sales were revealed, leaders shifted focus ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...

A new nasal drug has been approved to treat depression. The drug Spravato  is a nasal spray made by Johnson and Johnson.

Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.